Related references
Note: Only part of the references are listed.Cancer chemotherapy:: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity
Cedric Menard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Lionel Apetoh et al.
NATURE MEDICINE (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Dendritic cell-based vaccination combined with gemcitabine increases survival in a murine pancreatic carcinoma model
C. Bauer et al.
GUT (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
A clinical development paradigm for cancer vaccines and related biologics
Axel Hoos et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation
Yuriko Morita et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
A phase I/II trial of a WT1 (Wilms' tumor gene) peptide vaccine in patients with solid malignancy: Safety assessment based on the phase I data
Satoshi Morita et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2006)
Differences in immune cells engaged in cell-mediated immunity after chemotherapy for far advanced pancreatic cancer
S Bang et al.
PANCREAS (2006)
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients
P Correale et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
H Oettle et al.
ANNALS OF ONCOLOGY (2005)
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity
E Suzuki et al.
CLINICAL CANCER RESEARCH (2005)
Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas
JMD Plate et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2005)
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL response with antitumor activity in vitro
P Correale et al.
JOURNAL OF IMMUNOLOGY (2005)
Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial
C Louvet et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer
E Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression
Y Oka et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
Overexpression of the Wilms' tumor gene WT1 in pancreatic ductal adenocarcinoma
Y Oji et al.
CANCER SCIENCE (2004)
Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297
JD Berlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Actinomycin D and gemcitabine synergistically sensitize androgen-independent prostate cancer cells to Apo2L/TRAIL-mediated apoptosis
A Zisman et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Share Paper
